Advanced Therapeutics最新文献

{"title":"Dual-Targeted, pH/Reduction-Responsive Mesoporous Silica Nanocarriers for Selective Sorafenib Delivery to Hepatocellular Carcinoma","authors":"Sahra Perseh,&nbsp;Reza Bafkary,&nbsp;Hossein Salmani,&nbsp;Mohammad Hassan Shahriari,&nbsp;Rassoul Dinarvand,&nbsp;Ismaeil Haririan,&nbsp;Seyedeh Sahar Mojtabazadeh,&nbsp;Sanaz Jamshidfar,&nbsp;Mohammad Akrami","doi":"10.1002/adtp.202500581","DOIUrl":"https://doi.org/10.1002/adtp.202500581","url":null,"abstract":"<div>\u0000 \u0000 <p>Targeted nanocarriers offer a promising platform to improve cancer therapy by increasing efficacy while reducing off-target toxicity. A novel multilayer, reduction- and pH-responsive nanocarrier was engineered by sequentially functionalizing mesoporous silica nanoparticles with hyaluronic acid and polyamidoamine dendrimers, followed by conjugation with carboxyphenylboronic acid for dual receptor-mediated targeting of hepatocellular carcinoma cells. The nanoparticles were characterized by dynamic light scattering, showing size growth from 242.1 nm (bare) to 344.4 nm after complete coating, and a zeta potential shift from −30.1 to −7.46 mV. BET analysis confirmed preserved mesopores, with specific surface area decreasing only 1.5% from 183.2 to 180.1 m2 g⁻¹, maintaining high porosity for drug loading. Sorafenib loading reached an encapsulation efficiency of 32% and a loading capacity of 60.4%. In vitro release demonstrated stimulus responsiveness: 55.2% release at acidic pH 5.5 and 73.4% in the presence of 10 mM glutathione, vs. 20.2% at pH 7.4 without glutathione. In HepG2 cells, the targeted system yielded an IC₅₀ of 7.6 µg/mL after 48 h, representing 1.8- and 1.25-fold improvements over sorafenib and non-targeted nanoparticles, respectively. The platform integrates HA-CD44 and carboxyphenylboronic acid with pH/redox-sensitive release for hepatocellular carcinoma therapy, offering to improve efficacy while reducing toxicity.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 8","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Injectable Self-Healing Quaternized Chitosan/Oxidized Pectin Hydrogels for Targeted siRNA Nanoparticle Delivery in Breast Cancer Therapy","authors":"Tanawat Buntum,&nbsp;Nanthanit Jaruseranee,&nbsp;Mattaka Khongkow,&nbsp;Uracha Ruktanonchai,&nbsp;Hasan Uludağ,&nbsp;Orawan Suwantong","doi":"10.1002/adtp.202600001","DOIUrl":"https://doi.org/10.1002/adtp.202600001","url":null,"abstract":"<div>\u0000 \u0000 <p>This study explored the potential of siRNA nanoparticles-loaded quaternized chitosan and oxidized pectin (QCS/OxPec) injectable self-healing hydrogels for breast cancer therapy. The <i>SURVIVIN</i> siRNA (siSVV) nanoparticles were prepared using electrostatic interactions between siRNA, Trans-Booster, and Prime-Fect or modified polyethyleneimine (PEI). These nanoparticles exhibited significant growth inhibition and gene silencing in both breast cancer cell lines. The siSVV nanoparticles were incorporated into QCS/OxPec injectable self-healing to investigate the potential for use in breast cancer treatment. The effect of OxPec concentrations and the addition of siRNA on the properties of the hydrogels was investigated. The siSVV nanoparticles in the hydrogels showed uniform particles with spherical shapes. The siSVV nanoparticles-loaded injectable self-healing hydrogels demonstrated rapid gelation (13–18 min) with self-healing properties within 3–4 min after cutting. The extraction media from the siSVV nanoparticles loaded in the hydrogels displayed significantly different cytotoxicity to both breast cancer cells after treatment for 72 h compared with control siRNA nanoparticles and the non-treated group. Furthermore, the siSVV nanoparticles-loaded injectable self-healing hydrogels exhibited high cellular uptake within 72 h of treatment for both breast cancer cells.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organometallic Therapeutics and Drug Delivery Strategies for Alzheimer's Disease: Bridging Metal Chemistry and Neurodegeneration","authors":"Ashwini Gawade,&nbsp;Ashwin Kuchekar,&nbsp;Rohini Pujari","doi":"10.1002/adtp.70159","DOIUrl":"https://doi.org/10.1002/adtp.70159","url":null,"abstract":"<div>\u0000 \u0000 <p>Alzheimer's disease (AD) remains one of the most challenging neurodegenerative disorders to treat due to its multifactorial pathology and limited efficacy of current therapies. Although recent advances have focused on amyloid-targeting strategies, effective disease modification is hindered by poor brain penetration, unfavorable pharmacokinetics, and inability to address multiple pathological pathways simultaneously. Organometallic-based drug delivery systems have emerged as promising multifunctional platforms that combine the unique properties of metal-containing compounds with advanced nanocarrier technologies. This review highlights recent developments in organometallic therapeutics and delivery strategies for AD, focusing on pharmaceutical design, blood-brain barrier transport, controlled drug release, and neurotherapeutic potential. Various delivery platforms, including nanoparticles, liposomes, dendrimers, polymer conjugates, and metal-organic frameworks, are discussed in relation to their ability to enhance drug stability, biodistribution, targeting efficiency, and therapeutic efficacy. The therapeutic relevance of these systems is further examined through their capacity to modulate amyloid-β aggregation, oxidative stress, metal dyshomeostasis, tau pathology, and neuroinflammation. Preclinical evidence suggests that organometallic-based platforms offer advantages over conventional approaches by integrating targeted delivery with intrinsic therapeutic activity. Despite challenges related to safety, scalability, and regulatory translation, continued advances in material design and translational research may facilitate development of clinically viable disease-modifying therapies for AD.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Anti-TNF Agents and Ustekinumab for Postoperative Recurrence in Crohn's Disease: 10 Years of Experience","authors":"Zihan Chen,&nbsp;Jianming Lin,&nbsp;Xiaoling Li,&nbsp;Jieqing Huang,&nbsp;Linxin Liu,&nbsp;Zhirong Zeng,&nbsp;Xiaojun Zhuang","doi":"10.1002/adtp.202500474","DOIUrl":"https://doi.org/10.1002/adtp.202500474","url":null,"abstract":"<div>\u0000 \u0000 <p>Anti- tumor necrosis factor (TNF) agents are effective in preventing and treating postoperative recurrence (POR) in Crohn's disease (CD), while some patients have intolerance or fail treatment. Ustekinumab may offer an alternative, though data are limited. To compare the efficacy of anti-TNF agents with ustekinumab for preventing and treating POR in CD. Patients who initiated anti-TNF agents or ustekinumab within three months after surgery for POR prevention or after ileocolonoscopy with Rutgeerts score ≥ i2 for POR treatment were included. Endoscopic and clinical outcomes were evaluated. For preventing POR, 68 patients received anti-TNF agents and 34 received ustekinumab, showing no significant differences in endoscopic POR (<i>p</i> = 0.777). Ustekinumab had a lower rate of clinical POR (<i>p</i> = 0.004) and biological therapy discontinuation (<i>p</i> &lt; 0.001). For treating POR, 35 received anti-TNF agents and 27 received ustekinumab, with no significant differences in endoscopic improvement (<i>p</i> = 0.632) or remission (<i>p</i> = 0.285). Ustekinumab showed a higher clinical treatment success (<i>p</i> = 0.004). Among 12 patients switching to ustekinumab after anti-TNF failure, 41.7% showed endoscopic remission, and 83.3% achieved clinical treatment success. Ustekinumab has better clinical outcomes and treatment persistence than anti-TNF agents in preventing and treating endoscopic POR in CD.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148466924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Chia Mucilage-Collagen Bio-Integrative Biomatrix to Promote Soft Tissue Repair and Regeneration","authors":"Punam Kumari,&nbsp;Kiruba Kannan,&nbsp;Rachita Lakra,&nbsp;Manikantan Syamala Kiran","doi":"10.1002/adtp.70157","DOIUrl":"https://doi.org/10.1002/adtp.70157","url":null,"abstract":"<div>\u0000 \u0000 <p>Chia mucilage polysaccharides are widely used in the food and nutraceutical industries, and collagen is a well-known natural polymer in biomaterials. Although both have been extensively studied individually, their combined synergistic potential in wound management remains largely unexplored. A biomatrix comprising a combination of chia mucilage and collagen was engineered for applications in regenerating skin tissue. The resulting self-assembled chia mucilage-collagen biomatrix exhibited a densely interconnected, uniform 3D structure, providing robust structural support for the collagen component. This biomatrix displayed favorable attributes, including thermal resilience, proteolytic stability, biocompatibility, hemocompatibility, and pro-angiogenic potential, as observed in aortic explants. Additionally, it demonstrated excellent suitability as a wound-dressing material with significant wound-healing capabilities. Histological analysis revealed accelerated re-epithelization and increased collagen deposition in animals treated with the chia mucilage-collagen biomatrix compared to those treated with native collagen scaffolds. Notably, VEGFR2 expression was less pronounced in the reinforced collagen biomatrix than in native collagen, indicating the restoration of skin tissue at both anatomical and morphological levels, resembling its native state. This study underscores the promising potential of the chia mucilage-collagen biomatrix as an ideal wound dressing material and represents a pioneering step toward the development of multifunctional biomaterials based on polysaccharides and proteins.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148462823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microneedle-Assisted Systems for the Delivery of Proteolysis Targeting Chimeras (PROTACs)","authors":"Pooja Tiwary,&nbsp;Krishil Oswal,&nbsp;Aishwarya Shirke,&nbsp;Heena Maithania,&nbsp;Ryan Varghese,&nbsp;Lalit Kumar Vora","doi":"10.1002/adtp.70158","DOIUrl":"https://doi.org/10.1002/adtp.70158","url":null,"abstract":"<p>Cancer remains a major global health challenge with increasing incidence and mortality rates. While conventional therapies such as chemotherapy and radiotherapy are the standard, they often suffer from off-target toxicity and resistance. Although the specificity of targeted therapies has improved, challenges such as drug resistance and adverse effects still persist. Proteolysis-targeting chimeras (PROTACs) offer a novel approach by degrading rather than inhibiting these oncogenic proteins, which often have the potential to overcome resistance mechanisms. However, their clinical application is impeded by poor solubility, bioavailability, and inefficient tumor targeting. In response, microneedles (MNs) have emerged as an innovative transdermal delivery platform capable of localized, controlled, and minimally invasive drug administration. The ability of these MNs to enhance tissue penetration and drug retention makes them ideal for overcoming PROTAC delivery barriers in cancer. To provide context and evidence, relevant publications were collated from Google Scholar, PubMed, ScienceDirect, Dimensions AI, and EBSCO, using specific keywords such as “cancer,” “diagnosis,” “drug loading,” “drug transport,” “microneedles,” “PROTACs,” “protein degradation,” “transdermal drug delivery,” “targeted degradation,” and “ubiquitination”. We did not impose any restrictions on the publication date during the selection process of papers. However, it is imperative to underscore that the initial reports containing specified keywords began publication in 2016. MNs-assisted delivery of PROTACs offers a groundbreaking strategy for targeted cancer therapy by enhancing drug stability, bioavailability, and tumor specificity. This platform enables precise, localized, and minimally invasive drug delivery, often facilitating the co-delivery of synergistic agents and stimuli-responsive release. When engineered with biomolecular targeting and smart sensing capabilities, these microneedles can optimize therapeutic efficacy while minimizing risks stemming from systemic toxicity. The ability of MNs to integrate diagnostics and therapeutics highlights their role in advancing personalized medicine. As research continues to evolve, microneedle-enabled PROTAC delivery is poised to redefine cancer treatment paradigms, offering a highly adaptable, patient-centric, and next-generation therapeutic platform.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148462720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Issue Information (Adv. Therap. 7/2026)","authors":"","doi":"10.1002/adtp.70156","DOIUrl":"https://doi.org/10.1002/adtp.70156","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70156","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148322307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nucleic Acid-Based Vaccines in Ovarian Cancer: Progress, Challenges, and Future Prospects in Transforming the Immunotherapeutic Armamentarium","authors":"Namrata B. Parmar,&nbsp;Manya D. Desai,&nbsp;Khushi N. Mehta,&nbsp;Mehul R. Chorawala","doi":"10.1002/adtp.202500538","DOIUrl":"https://doi.org/10.1002/adtp.202500538","url":null,"abstract":"<div>\u0000 \u0000 <p>Ovarian cancer (OC) is a formidable adversary, often diagnosed at advanced stages with limited treatment options. This review article delves into the innovative and promising field of nucleic acid-based vaccines, which have ushered in a new era in cancer immunotherapy, particularly in the context of OC. These vaccines, utilizing both DNA and RNA platforms, offer a unique approach to harness the power of the immune system in targeting OC cells. Our exploration begins with a comprehensive overview of OC, emphasizing its heterogeneous nature and the pressing need for more effective therapies. We then elucidate the fundamental principles of immunotherapy and the role of the immune system in combating OC, setting the stage for the introduction of nucleic acid-based vaccines. The review delves into the mechanisms and design principles behind nucleic acid vaccines, highlighting their potential to trigger robust and specific immune responses. A critical examination of preclinical studies and clinical trials showcases the promising results achieved with these vaccines, offering hope to OC patients. Challenges, such as delivery and combination therapies, are discussed, alongside insights into the patient experience and quality of life improvements. Regulatory approvals and market dynamics are analyzed, revealing the evolving landscape of OC immunotherapy. We conclude with a discussion of the transformative impact of nucleic acid-based vaccines in this field and the potential for a brighter future in the battle against OC. Thus, the potential of nucleic acid-based vaccines offers optimism in the continuous effort to improve OC patients’ prognosis and quality of life.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148322308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pro-Apoptotic Peptides as Novel Therapeutics for Cancer: Current Status and Future Prospects","authors":"Aldo O. González-Cruz,&nbsp;José Juan Pérez-Trujillo,&nbsp;Mónica A. Ramírez-Cabrera,&nbsp;Isaías Balderas-Rentería,&nbsp;Sheila Adela Villa-Cedillo,&nbsp;Eder Arredondo-Espinoza","doi":"10.1002/adtp.202500426","DOIUrl":"https://doi.org/10.1002/adtp.202500426","url":null,"abstract":"<div>\u0000 \u0000 <p>Pro-apoptotic peptides have emerged as promising candidates in cancer therapeutics due to their ability to induce apoptosis in cancer cells while preferentially sparing normal tissues. By modulating intrinsic and extrinsic apoptotic pathways, these peptides offer a strategy to overcome drug resistance, a common challenge in conventional cancer treatments. Despite their potential, clinical translation is hindered by proteolytic instability, suboptimal delivery, and limited tumor specificity. Advances in peptide engineering, chemical modifications, and nanotechnology-based delivery systems have significantly enhanced their stability, bioavailability, and targeting capabilities. Additionally, developing tumor-penetrating peptides and stimuli-responsive delivery platforms has further improved therapeutic precision. Combination therapies incorporating pro-apoptotic peptides with chemotherapy, radiotherapy, or immunotherapy have demonstrated synergistic effects, enhancing efficacy and minimizing side effects. Preclinical studies and clinical trials involving compounds like plitidepsin, PEP-010, GO-203-2C, and CIGB-300 underscore the promise of these therapies, though further research is necessary to address current limitations. Overcoming delivery challenges, refining tumor-specific targeting, and expanding combination strategies will be essential for maximizing their therapeutic potential. This review highlights current advancements in pro-apoptotic peptide-based cancer therapies, including mechanisms of action, design strategies, and delivery systems. Moreover, we discuss challenges in clinical translation and explore future directions for optimizing their therapeutic potential.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 6","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148173714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosome-Based Vaccines as a Safe and Innovative Platform for Disease Prevention","authors":"Amir Hossein Kheirkhah,&nbsp;Alireza Rezapour","doi":"10.1002/adtp.202500497","DOIUrl":"https://doi.org/10.1002/adtp.202500497","url":null,"abstract":"<div>\u0000 \u0000 <p>Although conventional vaccines and recent mRNA-lipid nanoparticle platforms have revolutionized disease prevention, challenges remain regarding thermal stability, targeted delivery, and adverse immunogenic reactions. Exosomes, naturally occurring nanoscale extracellular vesicles (30–200 nm), have recently emerged as a highly innovative, biocompatible, and personalized platform for vaccine delivery. This comprehensive review systematically explores the latest advancements and structural innovations in exosome-based vaccines. To highlight the innovation of these biological vectors, we categorize and critically evaluate exosomes based on their distinct cellular origins: Dendritic Cell-derived exosomes (DEXs) possessing robust antigen-presenting capabilities; Tumor-derived exosomes (TDEs) harboring a rich repertoire of endogenous tumor antigens for cancer immunotherapy; and Plant-derived exosome-like nanovesicles (PELNVs) serving as an economical, highly scalable, and safe alternative vector. Furthermore, we provide a comparative analysis between exosome-based platforms and traditional vaccines, emphasizing their superior capacity to cross biological barriers, facilitate direct or cross-presentation of antigens, and elicit potent cellular and humoral immune responses. The therapeutic and prophylactic efficacies of these vaccines against various malignancies and severe infectious diseases (both viral, such as HIV, based on the “Trojan exosome” hypothesis, and non-viral) are thoroughly discussed. Finally, we summarize ongoing clinical trials, critically assess potential biosafety risks (such as off-target effects and oncogenic cargo transfer), and outline optimization strategies for large-scale manufacturing. Ultimately, exosome-based vaccines represent a paradigm shift in immunization, paving the way for next-generation personalized medicine.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 6","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148173713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}